APML4 A phase II trial in patients with previously untreated acute promyelocytic leukaemia to evaluate the effects of: (i) adding arsenic trioxide to all-trans retinoic acid and idarubicin for remission induction, and (ii) adding arsenic trioxide to all-trans retinoic acid as consolidation

DOI number 10.58109/yen7-mb13
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)

Australasian Leukaemia and Lymphoma Group (ALLG)

Harry Iland (Royal Prince Alfred Hospital)

Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data on 200 patients with acute non-lymphocytic leukaemia
  • High dose Ara-C daunorubicin and VP16-213 (HIDAC-37) versus conventional dose and complete remission in adults
  • Remission duration/survival
  • Toxicity of two treatment arms
  • Prognostic variables
  • Cytogenetics

Australasian Leukaemia and Lymphoma Group (ALLG)

Subject (ANZSRC Category)

Cancer therapy (excl. chemotherapy and radiation therapy)

ANZCTR Reference ACTRN12605000070639
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au